Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech
Alnylam (NASDAQ:ALNY) passes the Affordable Growth screen with strong growth, reasonable valuation, solid profitability, and healthy financials.
ChartMillyesterdayALNY
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo2 days agoALNY
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga2 days agoALNY
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass., September 02, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
Yahoo2 days agoALNY
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.
Benzinga2 days agoALNY
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Yahoo3 days agoALNY
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
Yahoo4 days agoALNY
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.
Yahoo4 days agoALNY
Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
Benzinga11 days agoALNY
Moderna's Melanoma Result Landed On A Market Positioned The Other Way
The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.
Yahoo14 days agoALNY
Biotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
Benzinga15 days agoALNY
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention
Decent Value screen flags Alnylam Pharmaceuticals (ALNY) for strong growth, solid profitability, and reasonable forward valuation.
ChartMill15 days agoALNY
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Benzinga16 days agoALNY
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318
BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.
Benzinga16 days agoALNY
Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis
CAMBRIDGE, Mass., August 18, 2026--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Brand
Yahoo17 days agoALNY
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Yahoo19 days agoALNY
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $316 to $256.
Benzinga21 days agoALNY
Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks
The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contributing to earnings growth during the current reporting season.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new invest
Yahoo23 days agoALNY
Drugs that missed the mark in pharma’s last earnings round
Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.
Yahoo24 days agoALNY
American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.
SeekingAlpha24 days agoALNY
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on an annualized basis producing an average annual return of 15.23%. Currently, Alnylam Pharmaceuticals has a market
Benzinga25 days agoALNY
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Yahoo29 days agoALNY
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2H 2027 $10 million Upfront Payment Received from Alnylam Collaboration Extends Cash Runway Through Q3 2027 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2026 (GLOBE NE
Yahoo29 days agoALNY
Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315
Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.
Benzingalast monthALNY
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $455
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $485 to $455.
Benzingalast monthALNY